Tutorials
Mirum Pharmaceuticals Inc logo

Mirum Pharmaceuticals Inc

$ 25.00 +0.25 (+1.01%) 08:09 PM EST
P/E:
At Loss
P/B:
7.38
Market Cap:
$ 818.79M
Enterprise V:
$ 696.11M
Volume:
293.87K
Avg Vol (2M):
318.33K
Also Trade In:
Volume:
293.87K
Market Cap $:
818.79M
PE Ratio:
At Loss
Avg Vol (2-Month):
318.33K
Enterprise Value $:
696.11M
PB Ratio:
7.38
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Mirum Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404
Description
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 55.07
Equity-to-Asset 0.37
Debt-to-Equity 0.02
Debt-to-EBITDA -0.06
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.19
Distress
Grey
Safe
Beneish M-Score 1.82
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
Name Current Vs Industry Vs History
5-Day RSI 43.85
9-Day RSI 49.43
14-Day RSI 51.68
6-1 Month Momentum % 15.59
12-1 Month Momentum % 70.89

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.26
Quick Ratio 3.16
Cash Ratio 2.77
Days Inventory 187.29
Days Sales Outstanding 79.38
Days Payable 481.12

Dividend & Buy Back

Name Current Vs Industry Vs History

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 87.15
Operating Margin % -396.16
Net Margin % -137.85
ROE % -53.96
ROA % -19.62
ROIC % -134.61
ROC (Joel Greenblatt) % -1672.54
ROCE % -18.48

Financials (Next Earnings Date:2022-11-15 Est.)

MIRM's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:MIRM

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 38.514
EPS (TTM) ($) -1.678
Beta 1.43
Volatility % 58.29
14-Day RSI 51.68
14-Day ATR ($) 1.994916
20-Day SMA ($) 24.8435
12-1 Month Momentum % 70.89
52-Week Range ($) 12.82 - 30.545
Shares Outstanding (Mil) 32.75

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Mirum Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More